Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3

Gut

Volumn 61, Issue 1, 2012, Pages 128-134

  Thompson, Alexander J ^a   Patel, Keyur ^a   Chuang, Wan Long ^b   Lawitz, Eric J ^c   Rodriguez Torres, Maribel ^d   Rustgi, Vinod K ^e   Flisiak, Robert ^f   Pianko, Stephen ^g   Diago, Moises ^h   Arora, Sanjeev ⁱ   Foster, Graham R ^j   Torbenson, Michael ^k   Benhamou, Yves ^l   Nelson, David R ^m   Sulkowski, Mark S ^k   Zeuzem, Stefan ⁿ   Pulkstenis, Erik ^o   Subramanian, G Mani ^o   McHutchison, John G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c Alamo Medical Research   (United States)

^d Fundacion de Investigacion de Diego   (Puerto Rico)

^e Metropolitan Research   (United States)

^f MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^g MONASH MEDICAL CENTRE   (Australia)

^h HOSPITAL QUIRÓN   (Spain)

ⁱ UNIVERSITY OF NEW MEXICO   (United States)

^j QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^k JOHNS HOPKINS UNIVERSITY   (United States)

^l PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^m UNIVERSITY OF FLORIDA   (United States)

ⁿ UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^o GLAXOSMITHKLINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBINTERFERON ALPHA2B; GAMMA GLUTAMYLTRANSFERASE; LIPID; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; IMMUNOLOGICAL PARAMETERS; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE; VIRAL CLEARANCE;

ADULT; ALBUMINS; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTERFERON-ALPHA; LINEAR MODELS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 83555177345     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.236158     Document Type: Article

References (39)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29(Suppl 1):74-81.
2. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008;134:416-23. (Pubitemid 351181308)
3. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003;125:1695-704. (Pubitemid 37500434)
4. Hickman IJ, Powell EE, Prins JB, et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003;39:1042-8. (Pubitemid 37523778)
5. Lecube A, Hernandez C, Genesca J, et al. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. Diabetes Care 2004;27:1171-5. (Pubitemid 38579785)
6. Lecube A, Hernandez C, Genesca J, et al. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care 2006;29:1096-101. (Pubitemid 44115250)
7. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004;165:1499-508.
8. Taura N, Ichikawa T, Hamasaki K, et al. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol 2006;101:2752-9. (Pubitemid 44902647)
9. Cua IH, Hui JM, Kench JG, et al. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008;48:723-31.
10. Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008;48:28-34. (Pubitemid 350191982)
11. Allison ME, Wreghitt T, Palmer CR, et al. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994;21:1135-9.
12. Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003;38:50-6. (Pubitemid 36775795)
13. Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000;133:592-9.
14. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999;29:328-33. (Pubitemid 29088433)
15. Caronia S, Taylor K, Pagliaro L, et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999;30:1059-63. (Pubitemid 29458297)
16. Zein CO, Levy C, Basu A, et al. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol 2005;100:48-55. (Pubitemid 41623268)
17. Wang CS, Wang ST, Yao WJ, et al. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol 2007;166:196-203.
18. Cua IH, Hui JM, Bandara P, et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 2007;46:66-73. (Pubitemid 47171922)
19. Veldt BJ, Chen W, Heathcote EJ, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008;47:1856-62. (Pubitemid 351945553)
20. Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008;135:111-21.
21. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-41. (Pubitemid 40585366)
22. Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008;48:721-7.
23. Dai CY, Huang JF, Hsieh MY, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009;50:712-18.
24. Conjeevaram HS, Kleiner DE, Everhart JE, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007;45:80-7. (Pubitemid 46144367)
25. Romero-Gomez M, Diago M, Andrade RJ, et al. Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009;50:1702-8.
26. Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007;102:570-6. (Pubitemid 46328143)
27. Delgado-Borrego A, Jordan SH, Negre B, et al. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 2010;8:458-62.
28. Giordanino C, Bugianesi E, Smedile A, et al. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. Am J Gastroenterol 2008;103:2481-7.
29. Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009;49:739-44.
30. Zeuzem S, Sulkowski MS, Lawitz EJ, et al. Albinterferon alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology 2010;139:1257-66.
31. Nelson DR, Benhamou Y, Chuang WL, et al. Albinterferon alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology 2010;139:1267-76.
32. WHO/IASO/IOTF. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Melbourne: Health Communications APL, 2000.
33. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63. (Pubitemid 30022895)
34. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
35. Pazienza V, Clement S, Pugnale P, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007;45:1164-71. (Pubitemid 46775778)
36. Miyamoto H, Moriishi K, Moriya K, et al. Involvement of the PA28gamma-dependent pathway in insulin resistance induced by hepatitis C virus core protein. J Virol 2007;81:1727-35. (Pubitemid 46214447)
37. Bernsmeier C, Duong FH, Christen V, et al. Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. J Hepatol 2008;49:429-40.
38. Georgopoulou U, Tsitoura P, Kalamvoki M, et al. The protein phosphatase 2A represents a novel cellular target for hepatitis C virus NS5A protein. Biochimie 2006;88:651-62. (Pubitemid 44081829)
39. Khattab M, Emad M, Abdelaleem A, et al. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 2010;30:447-54.